A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of advanced colorectal cancer.
Advanced Colorectal Cancer
DRUG: T3011|DRUG: Regorafenib
Adverse event, To evaluate the safety of intravenous T3011 in combination with oral regorafenib in the treatment of patients with advanced colorectal cancer., 28 days after EOT
Overall response rate (ORR), To evaluate the efficacy of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (ORR will be assessed according to RECIST 1.1 \& iRECIST), Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.|Disease control rate (DCR), To evaluate the DCR of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (DCR will be assessed according to RECIST 1.1 \& iRECIST), Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.|Progression-free Survival (PFS), To evaluate the PFS of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer (PFS will be assessed according to RECIST 1.1 \& iRECIST), Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 24 months.|Overall survival (OS), To evaluate the OS of intravenous T3011 combined with oral regorafenib in the treatment of patients with advanced colorectal cancer, 24 months|Quality of life questionnaire (QLQ-C30), The EORTC Core Questionnaire (QLQ-C30) is widely used to measure quality of life in oncology. For self-reported general health and psychological distress, a higher score indicated worse health., Up to 24 months
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of advanced colorectal cancer.